Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study

Lancet Haematol. 2016 Jun;3(6):e284-92. doi: 10.1016/S2352-3026(16)30019-9. Epub 2016 May 9.

Abstract

Background: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Knowledge about the immunogenicity of red-blood-cell antigens can help optimise risk-adapted matching strategies. We set out to assess the immunogenicity of red-blood-cell antigens.

Methods: In an incident new-user cohort of previously non-transfused, non-alloimmunised white patients receiving non-extended matched red-blood-cell transfusions in six Dutch hospitals between 2006 and 2013, we determined the cumulative number of mismatched red-blood-cell units per patient. We used multiple imputation to address missing antigen data. Using Kaplan-Meier analysis, we estimated cumulative alloimmunisation incidences per mismatched antigen dose as a measure of immunogenicity.

Findings: Of 54 347 patients assessed, 21 512 were included in our study. Alloantibodies occurred in 474 (2·2%) of all transfused patients, with cumulative alloimmunisation incidences increasing up to 7·7% (95% CI 4·9-11·2) after 40 units received. The antigens C, c, E, K, and Jk(a) were responsible for 78% of all alloimmunisations in our cohort. K, E, and C(w) were the most immunogenic antigens (cumulative immunisation incidences after 2 mismatched units of 2·3% [95% CI 1·0-4·8] for K, 1·5% [0·6-3·0] for E, and 1·2% [0·0-10·8] for C(w)). These antigens were 8·7 times (for K), 5·4 times (for E), and 4·6 times (for C(w)) as immunogenic as Fy(a). The next most immunogenic antigens were, in order, e (1·9 times as immunogenic as Fy(a)), Jk(a) (1·9 times), and c (1·6 times).

Interpretation: Red-blood-cell antigens vary in their potency to evoke a humoral immune response. Our findings highlight that donor-recipient red-blood-cell matching strategies will be most efficient when primarily focusing on prevention of C, c, E, K, and Jk(a) alloimmunisation. Matching for Fy(a) is of lower clinical relevance. Variations of antigen frequencies determined by ethnic background prevent extrapolating these conclusions to non-white populations.

Funding: None.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Group Antigens / immunology*
  • Blood Group Incompatibility / blood
  • Blood Group Incompatibility / epidemiology*
  • Blood Group Incompatibility / immunology
  • Blood Grouping and Crossmatching / methods*
  • Child
  • Child, Preschool
  • Cohort Studies
  • Erythrocyte Transfusion*
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Infant
  • Isoantibodies / blood*
  • Isoantibodies / immunology
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Prognosis
  • Survival Rate
  • Transfusion Reaction / immunology*
  • Young Adult

Substances

  • Blood Group Antigens
  • Isoantibodies